| Yin, Yongmei |
NCT06143553: Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer |
|
|
| Recruiting | 3 | 168 | RoW | Paclitaxel Polymeric Micelles for Injection, Eribulin Mesilate injection, Capecitabine Tablets, Gemcitabine Hydrochloride for Injection, Vinorelbine Tartrate Injection, Paclitaxel (albumin-bound) | Shanghai Yizhong Pharmaceutical Co., Ltd. | Metastatic Breast Cancer (MBC) | 12/25 | 12/25 | | |
TORCHLIGHT, NCT04085276: Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment |
|
|
| Active, not recruiting | 3 | 531 | RoW | JS001, Nab-Paclitaxel, Placebo | Shanghai Junshi Bioscience Co., Ltd. | Triple-Negative Breast Cancer | 12/24 | 12/25 | | |
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer |
|
|
| Active, not recruiting | 3 | 866 | Europe, Japan, US, RoW | Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219 | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasms, Neoplasm Metastasis | 06/24 | 08/27 | | |
TQB3616-Ⅲ-02, NCT05365178: To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer |
|
|
| Active, not recruiting | 3 | 432 | RoW | TQB3616 capsule, Placebo, Fulvestrant injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | HR-positive, HER2-negative Breast Neoplasms | 06/24 | 06/26 | | |
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer |
|
|
| Recruiting | 3 | 360 | RoW | PM8002, Nab-Paclitaxel, Placebo | Biotheus Inc. | Triple Negative Breast Cancer(TNBC) | 07/27 | 07/28 | | |
JSKN003-302, NCT06079983: JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects |
|
|
| Not yet recruiting | 3 | 400 | RoW | JSKN003, Capecitabine tablets, Gemcitabine hydrochloride for injection, Vinorelbine tartrate injection, Paclitaxel for injection (albumin-bound type), Docetaxel injection, Eribulin mesylate injection | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Breast Cancer | 04/25 | 03/29 | | |
| Recruiting | 3 | 314 | RoW | Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502), Control drug: Trastuzumab emtansine (Kadcyla, T-DM1) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Breast Cancer | 07/25 | 01/26 | | |
LEONARDA-2, NCT05851014: A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer |
|
|
| Recruiting | 3 | 350 | RoW | GB491 combined with Letrozole, Placebo combined with Letrozole | Genor Biopharma Co., Ltd. | Breast Cancer | 01/26 | 01/27 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
| Active, not recruiting | 2/3 | 549 | Europe, RoW | Oral paclitaxel, Liporaxel®, Paclitaxel injection, Taxol® | Daehwa Pharmaceutical Co., Ltd., Daehwa pharmaceutical Co., Ltd. | Recurrent or Metastatic Breast Cancer | 02/24 | 12/25 | | |
NCT05860465: Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer |
|
|
| Recruiting | 2/3 | 254 | RoW | SPH4336 Tablets, SPH4336 Tablets Placebo | Shanghai Pharmaceuticals Holding Co., Ltd | Locally Advanced or Metastatic Breast Cancer | 03/25 | 08/25 | | |
NCT06254690: The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study |
|
|
| Recruiting | 2 | 102 | RoW | Pyrotinib dose escalation, Trastuzumab, Docetaxel, Pyrotinib dose normal | The First Affiliated Hospital with Nanjing Medical University, Zhongda Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Jingjiang People's Hospital, Yancheng First People's Hospital, Affiliated Hospital of Jiangnan University, Affiliated Hospital of Nantong University, Anhui Provincial Cancer Hospital, Huai'an First People's Hospital, The Affiliated Hospital of Xuzhou Medical University, Suzhou Municipal Hospital, Affiliated Hospital of Jiangsu University | Breast Cancer | 11/26 | 12/26 | | |
NCT05336721: A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC |
|
|
| Terminated | 2 | 9 | RoW | Chiauranib, capecitabine | Chipscreen Biosciences, Ltd. | Triple-negative Breast Cancer | 10/24 | 11/24 | | |
| Not yet recruiting | 2 | 33 | RoW | TQB3616 capsule+Fulvestrant Injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Breast Cancer | 05/26 | 12/26 | | |
| Recruiting | 2 | 175 | RoW | SKB264, KL-A167 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Triple-negative Breast Cancer and HR+/HER2- BC | 04/25 | 07/25 | | |
| Recruiting | 2 | 402 | RoW | SHR-A1811：Pyrotinib, SHR-A1811；Pertuzumab, SHR-A1811；Adebrelimab, SHR-A1811；Albumin paclitaxel | Jiangsu HengRui Medicine Co., Ltd. | Breast Cancer | 12/25 | 12/25 | | |
NCT05872347: Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases. |
|
|
| Recruiting | 2 | 52 | RoW | SPH4336 Tablets | Shanghai Pharmaceuticals Holding Co., Ltd | Breast Cancer Brain Metastases | 12/25 | 12/25 | | |
| Recruiting | 1/2 | 380 | RoW | PM8002 | Biotheus Inc. | Malignant Neoplasm | 11/25 | 11/25 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
| Recruiting | 1/2 | 725 | RoW | JSKN003 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Solid Tumor | 12/24 | 12/26 | | |
|
SHR-A1811-207, NCT05845138: A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression. |
|
|
| Recruiting | 1/2 | 116 | RoW | SHR-A1811 for injection ; capecitabine | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Breast Cancer | 12/24 | 12/25 | | |
| Recruiting | 1/2 | 60 | RoW | PM8002, nab-paclitaxel | Biotheus Inc. | TNBC | 10/26 | 10/26 | | |
| Recruiting | 1 | 70 | RoW | TQB3915 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Malignant Tumor | 06/23 | 06/24 | | |
NCT06770296: The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study |
|
|
| Recruiting | 1 | 200 | RoW | Pyrotinib low dose group, Pyrotinib normal dose group | The First Affiliated Hospital with Nanjing Medical University, The First People's Hospital of Xuzhou, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, The Second People's Hospital of Changshu, Shuyang County Traditional Chinese Medicine Hospital, Affiliated Hospital of Nantong University, Affiliated Hospital of Jiangsu University, The Affiliated Hospital of Xuzhou Medical University | Breast Cancer | 11/26 | 11/28 | | |
NCT05473624: Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 153 | RoW | HRS-1167 | Jiangsu HengRui Medicine Co., Ltd. | Advanced Solid Tumors | 12/24 | 12/24 | | |
NCT05764941: Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer |
|
|
| Recruiting | N/A | 100 | RoW | Inetetamab, Pyrotinib, Vinorelbine | The First Affiliated Hospital with Nanjing Medical University | Breast Neoplasms | 03/24 | 03/24 | | |
THALIA-01, NCT05231863: Tyrosine Kinase Inhibitors (TKIs) in Trastuzumab Emtansine (T-DM1) Resistant HER2-positive Metastatic Breast Cancer: A Real-world Study |
|
|
| Recruiting | N/A | 100 | RoW | TKIs | The First Affiliated Hospital with Nanjing Medical University | Breast Cancer | 12/22 | 12/22 | | |
ALOT-BC1, NCT05334147: Anlotinib Combined With Chemotherapy for the Treatment of HER2 Negative Advanced Breast Cancer |
|
|
| Not yet recruiting | N/A | 315 | NA | | The First Affiliated Hospital with Nanjing Medical University | HER2-negative Breast Cancer | 02/25 | 09/25 | | |
| Liu, Hongli |
NCT05625737: Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma |
|
|
| Active, not recruiting | 2 | 29 | RoW | Fruquintinib, Sintilimab | Wuhan Union Hospital, China | Stomach Neoplasms | 12/24 | 09/25 | | |
NCT06434610: A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer. |
|
|
| Recruiting | 2 | 90 | RoW | B013, Paclitaxel, Placebo | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Platinum-resistant Recurrent Ovarian Cancer | 12/26 | 12/26 | | |
TQB2102-II-04, NCT06767800: A Clinical Trial Evaluating TQB2102 for Injection in Combination With Benmelstobart/Penpulimab With or Without Capecitabine in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma |
|
|
| Not yet recruiting | 2 | 168 | RoW | TQB2102 for injection+Benmelstobart, TQB2102 for injection+Benmelstobart+Capecitabine | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Gastroesophageal Adenocarcinoma | 09/26 | 09/27 | | |
NCT05879055: A Study of PM8002 in Combination With Chemotherapy in Patients With NEN |
|
|
| Recruiting | 2 | 60 | RoW | PM8002, FOLFIRI | Biotheus Inc. | Neuroendocrine Neoplasm | 01/27 | 01/28 | | |
NCT05155124: Safety of Cetuximab and Trifluridin Tipiracil as the Third-line Therapy in the RASwt mCRC |
|
|
| Recruiting | 1 | 6 | RoW | Cetuximab + trifluridin tipiracil, Erbitux；TAS102;TAS-102 | Wuhan Union Hospital, China | Colorectal Neoplasms Malignant | 10/22 | 04/23 | | |
NCT05638269: A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China |
|
|
| Recruiting | N/A | 12000 | RoW | no intervention | Zhujiang Hospital, National Natural Science Foundation of China | Essential Hypertension, Liver Cancer, Nasopharyngeal Cancer, Pancreatic Cancer, Lung Cancer, Chronic Kidney Diseases, Acute Coronary Syndrome, Epilepsy, Gastric Cancer, Primary Aldosteronism, Subclinical hypothyroïdism | 12/24 | 12/25 | | |
